Medica SurB de CVMEX:MEDICAB 84 EBITDA Margin % is 23.90% as of Dec. 2025, which is 6% above its 10-year median of 22.54. GuruFocus rates MEX:MEDICAB with a GF Score™ of 84/100 and a GF Value™ of MXN47.66 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Medica SurB de CV ranks better than 81.44% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Medica SurB de CV's EBITDA for the
three
months ended in Dec. 2025 was MXN292 Mil. Medica SurB de CV's Revenue for the
three
months ended in Dec. 2025 was MXN1,223 Mil. Therefore, Medica SurB de CV's EBITDA margin for the quarter that ended in Dec. 2025 was 23.90%.
Medica SurB de CV (MEX:MEDICAB) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Medica SurB de CV EBITDA Margin % Related Terms
Medica SurB de CV EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Medica SurB de CV's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:MEDICAB vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Medica SurB de CV's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medica SurB de CV EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Medica SurB de CV's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Medica SurB de CV's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medica SurB de CV (MEX:MEDICAB) has a EBITDA Margin % of 23.90% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medica SurB de CV and its competitors. This is near median its historical median of 22.54. Over the past decade, Medica SurB de CV's EBITDA Margin % has ranged from 17.44 to 29.52. According to the industry distribution chart, Medica SurB de CV ranks #124 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 18.6%.
Is Medica SurB de CV's EBITDA Margin % too high?
Medica SurB de CV's current EBITDA Margin % of 23.90% is near median its 10-year median of 22.54. Over the past 10 years, this metric has ranged from a low of 17.44 to a high of 29.52. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Medica SurB de CV's value of 23.90% is 134.1% above this industry median. Based on the distribution chart, Medica SurB de CV ranks #124 out of 668 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Medica SurB de CV has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medica SurB de CV's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Medica SurB de CV ranks #124 out of 668 companies for EBITDA Margin %. This places Medica SurB de CV in the top 19% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.21. Medica SurB de CV's value of 23.90% is 134.1% above this benchmark. Historically, Medica SurB de CV's own EBITDA Margin % has ranged from 17.44 to 29.52 over the past decade. While the company's 10-year median is 22.54 vs. the industry median of 10.21, Medica SurB de CV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medica SurB de CV's current EBITDA Margin % of 23.90% is 134.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medica SurB de CV and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medica SurB de CV's current EBITDA Margin % is 23.90%, which is near median its own 10-year median of 22.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medica SurB de CV stock overvalued right now?
Based on GuruFocus' analysis, Medica SurB de CV (MEX:MEDICAB) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN47.66, compared to a current price of MXN60.77 — trading 27.5% above its estimated fair value. The current EBITDA Margin % is 23.90%, which is near median its 10-year median of 22.54 and 134.1% above the Healthcare Providers & Services industry median of 10.21. Medica SurB de CV's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Medica SurB de CV (MEX:MEDICAB), the current EBITDA Margin % is 23.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medica SurB de CV (MEX:MEDICAB) Overvalued in 2026?
Based on GuruFocus' analysis, Medica SurB de CV stock appears to be overvalued.
The current stock price of MXN60.77 is trading 27.5% above its estimated GF Value™ of MXN47.66.
GuruFocus considers Medica SurB de CV to be Modestly Overvalued.
Key valuation signals for MEX:MEDICAB:
EBITDA Margin %: 23.90% (near median its 10-year median of 22.54)
GF Value™: MXN47.66 vs. price of MXN60.77 (27.5% above fair value)
Industry Position: 134.1% above the Healthcare Providers & Services median (#124 of 668)
No single metric tells the full story. See the MEX:MEDICAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medica Sur SAB de CV is a medical care company specializes in emergency scenarios. The company offers emergency ambulance transportation, air transportation and paramedic assistance.
84GF Score
Get the complete analysis for MEX:MEDICAB
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:MEDICAB has been successfully added to your 
